HIV-1 sequence diversity presents a major challenge for the clinical development of broadly
neutralizing antibodies (bNAbs) for both therapy and prevention. Sequence variation in …

Broadly neutralizing antibodies (bNAbs) represent an alternative to drug therapy for the
treatment of HIV-1 infection. Immunotherapy with single bNAbs often leads to emergence of …

Recently identified broadly neutralizing antibodies (bNAbs) that potently neutralize most HIV-
1 strains are key to potential antibody-based therapeutic approaches to combat HIV/AIDS in …

Broadly neutralizing antibodies (bNAbs) represent a promising approach to prevent and
treat HIV-1 infection. However, viral escape through mutation of the HIV-1 envelope …

In the absence of an effective and safe vaccine against HIV-1, the administration of broadly
neutralizing antibodies (bNAbs) represents a logical alternative approach to prevent virus …

Broadly neutralizing antibodies (BnAbs) protect macaques from cell-free simian/human
immunodeficiency virus (SHIV) challenge, but their efficacy against cell-associated SHIV is …

The design of next-generation bNAb-based combination or multispecific therapeutics for the
prevention and/or treatment of HIV-1 infection will need to leverage the complementarity of …

Some HIV-1–infected patients develop broad and potent HIV-1 neutralizing antibodies
(bNAbs) that when passively transferred to mice or macaques can treat or prevent infection …

Anti-HIV broadly neutralizing antibodies (bnAbs) have revealed vaccine targets on the
virus's envelope (Env) protein and are themselves promising immunotherapies. The efficacy …

For the development of a neutralizing antibody-based human immunodeficiency virus type 1
(HIV-1) vaccine, it is important to characterize which antibody specificities are most effective …